Mantle cell lymphoma

21 trials 10 recruiting MedDRA PT
21 Registered trials
10 Recruiting
15 Unique sponsors
20 Unique IMPs
12 Commercial trials
Drug classes (ATC)
— ATC code not specified 14
L Oncology (ATC L) 7
N Neurology/Psychiatry (ATC N) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 7 substances
BTK inhibitor 6 substances
Monoclonal antibody (chimeric) 1 substance
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody (rat) 1 substance
IMiD 1 substance
CAR-T cell therapy 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
BCL-2 inhibitor 1 substance
Phase III: 2 Phase II/III: 1 Phase II: 9 Phase I/II: 3 Phase IV: 1 Phase I: 3 Phase I (First in Human): 2

Filter these 21 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 21 trials

Phase III

2 trials
  • BeOne Medicines AG Commercial
    N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SULFONYL]-4-(2-{(2S)-2-[2-(PROPAN-2-YL)PHENYL]PYRROLIDIN1-YL}-7-AZASPIRO[3.5]NONAN-7-YL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5- YL)OXY]BENZAMIDE; ZANUBRUTINIB
    2024-515593-27-00 6 countries 2025 n=140
    Recruiting
  • Innocare Pharma Inc. Commercial
    BENDAMUSTINE HYDROCHLORIDE; ORELABRUTINIB; RITUXIMAB
    2025-524241-27-00 5 countries n=102
    Pending

Phase II/III

1 trial
  • BeOne Medicines AG Commercial
    BENDAMUSTINE HYDROCHLORIDE; RITUXIMAB; ZANUBRUTINIB
    2023-509908-15-00 11 countries 2020 n=267
    Ended

Phase II

9 trials
  • AstraZeneca AB Commercial
    CAPIVASERTIB
    2024-516386-36-00 1 country 2022 n=1
    Ended
  • Merck Sharp & Dohme LLC Commercial
    NEMTABRUTINIB; ZILOVERTAMAB VEDOTIN
    2022-501374-19-00 9 countries 2022 n=103
    Recruiting
  • Regeneron Pharmaceuticals Inc. Commercial
    ODRONEXTAMAB
    2024-511747-25-00 5 countries 2019 n=225 Orphan
    Ended
  • Fondazione IRCCS Istituto Nazionale Dei Tumori Academic
    BREXUCABTAGENE AUTOLEUCEL; IBRUTINIB
    2022-502907-31-00 1 country 2023 n=20 Orphan
    Expired
  • Fondazione Italiana Linfomi Ets Academic
    IMP not specified
    2024-511533-35-00 1 country 2018 n=130
    Ended
  • Fondazione Italiana Linfomi Ets Academic
    IMP not specified
    2025-521666-10-01 1 country 2026 n=56
    Recruiting
  • Fondazione Italiana Linfomi Ets Academic
    IMP not specified
    2025-523428-39-00 1 country 2026 n=41
    Recruiting
  • Fundacion Geltamo Academic
    PIRTOBRUTINIB; RITUXIMAB
    2024-511983-97-00 2 countries 2025 n=50
    Recruiting
  • Fundacion Geltamo Academic
    IBRUTINIB; RITUXIMAB
    2024-512370-94-00 1 country 2024 n=50
    Ended

Phase I/II

3 trials
  • AstraZeneca AB Commercial
    ACALABRUTINIB; HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST CD3 AND CD19; SUROVATAMIG
    2024-515034-33-00 5 countries 2025 n=200
    Recruiting
  • Celgene Corp. Commercial
    GOLCADOMIDE; VALEMETOSTAT TOSILATE
    2024-515690-10-00 4 countries 2019 n=204 Orphan
    Ended
  • Centre Hospitalier Universitaire De Nantes Academic
    IBRUTINIB; OBINUTUZUMAB; VENETOCLAX
    2024-516750-21-00 1 country 2015 n=44 Orphan
    Ended

Phase IV

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IBRUTINIB
    2023-507329-40-00 7 countries 2017 n=125
    Ended

Phase I

3 trials
  • Miltenyi Biomedicine GmbH Commercial
    AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD19
    2024-513334-38-00 1 country 2018 n=49
    Ended
  • Nurix Therapeutics Inc. Commercial
    IMP not specified
    2023-510541-25-00 5 countries 2023 n=250
    Recruiting
  • Universitaetsklinikum Wuerzburg AöR Academic
    IMP not specified
    2024-512019-36-00 1 country 2025 n=44
    Recruiting

Phase I (First in Human)

2 trials
  • BeOne Medicines AG Commercial
    IMP not specified
    2022-502157-33-00 5 countries 2023 n=239
    Recruiting
  • Uppsala Universitet Academic
    IMP not specified
    2024-511844-18-00 1 country 2024 n=30
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
BeOne Medicines AG Commercial 3 Phase II/III, Phase III, Phase I (First in Human) 2
Fondazione Italiana Linfomi Ets Academic 3 Phase II 2
AstraZeneca AB Commercial 2 Phase II, Phase I/II 1
Fundacion Geltamo Academic 2 Phase II 1
Miltenyi Biomedicine GmbH Commercial 1 Phase I 0
Nurix Therapeutics Inc. Commercial 1 Phase I 1
Merck Sharp & Dohme LLC Commercial 1 Phase II 1
Regeneron Pharmaceuticals Inc. Commercial 1 Phase II 0
Innocare Pharma Inc. Commercial 1 Phase III 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase IV 0
Celgene Corp. Commercial 1 Phase I/II 0
Universitaetsklinikum Wuerzburg AöR Academic 1 Phase I 1
Fondazione IRCCS Istituto Nazionale Dei Tumori Academic 1 Phase II 0
Uppsala Universitet Academic 1 Phase I (First in Human) 1
Centre Hospitalier Universitaire De Nantes Academic 1 Phase I/II 0
New trials by year
2019
2
2020
1
2022
2
2023
3
2024
2
2025
4
2026
2
← All indication landscapes